N. Moore

5.3k total citations · 2 hit papers
27 papers, 4.0k citations indexed

About

N. Moore is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, N. Moore has authored 27 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in N. Moore's work include Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Glioma Diagnosis and Treatment (6 papers). N. Moore is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Glioma Diagnosis and Treatment (6 papers). N. Moore collaborates with scholars based in Switzerland, Germany and France. N. Moore's co-authors include Bernard Escudier, Alain Ravaud, Cezary Szczylik, Sergio Bracarda, Natasha B. Leighl, Christine Chevreau, A Płużańska, P. Koralewski, Bohuslav Melichar and M. Filipek and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

N. Moore

27 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

2009 1.2k citations Martin Reck, Petr Zatloukal et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Moore Switzerland	16	2.6k	2.0k	1.7k	1.2k	460	27	4.0k
Sang‐We Kim South Korea	36	3.9k 1.5×	3.5k 1.8×	1.4k 0.8×	743 0.6×	306 0.7×	207	5.4k
Jin‐Ji Yang China	36	3.9k 1.5×	3.5k 1.8×	1.2k 0.7×	1.1k 0.9×	157 0.3×	146	4.9k
Janice Dutcher United States	9	2.6k 1.0×	1.1k 0.5×	2.4k 1.4×	1.4k 1.1×	186 0.4×	13	3.6k
Norbert Hollaender Switzerland	15	2.5k 1.0×	1.0k 0.5×	2.4k 1.4×	1.3k 1.1×	362 0.8×	29	4.0k
E Solska United States	4	3.9k 1.5×	1.9k 0.9×	3.3k 1.9×	2.1k 1.7×	152 0.3×	7	5.5k
Zsuzsanna Pápai Hungary	20	1.6k 0.6×	1.7k 0.9×	1.2k 0.7×	951 0.8×	343 0.7×	94	3.2k
Yaroslav Shparyk United States	24	2.4k 0.9×	3.0k 1.5×	870 0.5×	965 0.8×	400 0.9×	70	3.9k
Peter Langmuir United States	30	1.6k 0.6×	1.8k 0.9×	1.3k 0.8×	507 0.4×	384 0.8×	56	4.7k
David A. Ramies United States	18	2.9k 1.1×	2.7k 1.4×	1.2k 0.7×	608 0.5×	136 0.3×	37	3.8k
Mircea Dediu Romania	19	5.1k 2.0×	4.8k 2.4×	1.6k 0.9×	894 0.7×	152 0.3×	55	6.6k

Countries citing papers authored by N. Moore

Since Specialization

Citations

This map shows the geographic impact of N. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Moore more than expected).

Fields of papers citing papers by N. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Moore. The network helps show where N. Moore may publish in the future.

Co-authorship network of co-authors of N. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of N. Moore. A scholar is included among the top collaborators of N. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Moore. N. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sandmann, Thomas, Richard Bourgon, Josep Garcia, et al.. (2015). Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of Clinical Oncology. 33(25). 2735–2744. 208 indexed citations

Seymour, John F., M Pfreundschuh, Marek Trněný, et al.. (2014). R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 99(8). 1343–1349. 76 indexed citations

Bais, Carlos, Christina Rabe, Norbert Wild, et al.. (2014). Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications).. Journal of Clinical Oncology. 32(15_suppl). 3040–3040. 17 indexed citations

Gianni, Luca, Gilles Romieu, М. Р. Личиницер, et al.. (2013). AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. Journal of Clinical Oncology. 31(14). 1719–1725. 199 indexed citations

Gianni, Luca, Arlene Chan, Mauro Mansutti, et al.. (2012). Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC). Annals of Oncology. 23. ix531–ix532. 4 indexed citations

Leighl, Natasha B., Jaafar Bennouna, Yi Jiang, et al.. (2011). Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. British Journal of Cancer. 104(3). 413–418. 43 indexed citations

Mok, Tony, Chun-Ming Tsai, Kenneth W.T. Tsang, et al.. (2011). Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial. Asia-Pacific Journal of Clinical Oncology. 7(s2). 4–12. 37 indexed citations

Chinot, Olivier, T. De La Motte Rouge, N. Moore, et al.. (2011). AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Advances in Therapy. 28(4). 334–340. 149 indexed citations

Gianni, Luca, Gilles Romieu, M. Lichinitser, et al.. (2011). S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research. 71(24_Supplement). S4–8. 29 indexed citations

10.

Leighl, Natasha B., Petr Zatloukal, J. Mezger, et al.. (2010). Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL). Journal of Thoracic Oncology. 5(12). 1970–1976. 82 indexed citations

11.

Chinot, Olivier, et al.. (2009). 8713 Addition of bevacizumab to the multi-modality standard of care in patients with newly diagnosed glioblastoma: a phase III trial. European Journal of Cancer Supplements. 7(2). 497–497. 2 indexed citations

12.

Leighl, N. B., Petr Zatloukal, J. Mezger, et al.. (2009). Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL). Journal of Clinical Oncology. 27(15_suppl). 8050–8050. 15 indexed citations

13.

Henderson, Sarah B., N. Moore, Emma Lee, & Miles D. Witham. (2008). Do the malnutrition universal screening tool (MUST) and Birmingham nutrition risk (BNR) score predict mortality in older hospitalised patients?. BMC Geriatrics. 8(1). 26–26. 43 indexed citations

14.

Bajetta, E., Alain Ravaud, Sergio Bracarda, et al.. (2008). Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 26(15_suppl). 5095–5095. 18 indexed citations

15.

Escudier, Bernard, A Płużańska, P. Koralewski, et al.. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet. 370(9605). 2103–2111. 1722 indexed citations breakdown →

16.

Eberhardt, Wilfried, Martin Reck, Petr Zatloukal, et al.. (2007). 6518 ORAL Subgroup results from a randomised, double-blind, multicentre phase III study of bevacizumab in combination with cisplatingemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): study BO17704. European Journal of Cancer Supplements. 5(4). 362–362. 3 indexed citations

17.

Manegold, C., Petr Zatloukal, Rodryg Ramlau, et al.. (2007). 6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 5(4). 357–357. 7 indexed citations

18.

Bracarda, Sergio, P. Koralewski, A Płużańska, et al.. (2007). 4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements. 5(4). 281–282. 5 indexed citations

19.

Escudier, Bernard, P. Koralewski, A Płużańska, et al.. (2007). A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology. 25(18_suppl). 3–3. 85 indexed citations

20.

Bennouna, Jaafar, Petr Zatloukal, Rodryg Ramlau, et al.. (2007). 6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704. European Journal of Cancer Supplements. 5(4). 359–359. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact